{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:23:38Z","timestamp":1787649818001,"version":"build-2736575974"},"reference-count":43,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Aging frailty is a multifactorial geriatric syndrome characterized by reduced physiological reserve across multiple interrelated systems, leading to increased vulnerability to adverse health outcomes. Mesenchymal stem cells (MSCs) have emerged as a potential therapeutic intervention due to their immunomodulatory and regenerative properties. This systematic review aimed to evaluate the available clinical evidence regarding the safety and efficacy of MSC administration in individuals with aging frailty. A systematic literature search was conducted in PubMed, Scopus, and the Cochrane Library from database inception to 15 April 2026. Only randomized controlled trials (RCTs) were eligible. Data were extracted according to study design, participants\u2019 characteristics, MSC source and dosing, safety outcomes, functional performance measures, quality of life (QoL) indices, and inflammatory, immune, and vascular biomarkers. Three RCTs met the inclusion criteria, comprising a total of approximately 208 participants. MSC administration was well-tolerated, with no treatment-related serious adverse events reported. Signals of improvement were reported in mobility-related and physical performance outcomes, although the magnitude and consistency of the response varied across studies. A dose-dependent increase in 6 min walk distance was observed at nine months in one trial, while improvements in SPPB, TUG, and grip strength were reported in the other studies. Additionally, MSC therapy was associated with QoL improvement and reduction in circulating pro-inflammatory cytokine concentrations. MSC administration was also associated with changes in immune-cell activation and a dose-dependent reduction in circulating sTIE2. Because of substantial clinical and methodological heterogeneity among the included trials, a quantitative meta-analysis was not performed. Current randomized evidence remains limited but suggests that intravenous MSC therapy is generally well tolerated in older adults with aging frailty and may produce clinically relevant signals of improvement in mobility-related functional outcomes, quality of life, and selected inflammatory, immune, and vascular biomarkers. However, the small number of trials, heterogeneity in MSC source, dose, endpoints, and follow-up duration, and the exploratory nature of much of the evidence preclude definitive conclusions regarding efficacy. Larger, adequately powered trials with standardized frailty endpoints are required, while future trials specifically targeting sarcopenia should apply consensus diagnostic criteria and direct measures of muscle quantity, strength, and physical performance.<\/jats:p>","DOI":"10.3390\/ijms27177596","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:04:30Z","timestamp":1787648670000},"page":"7596","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Mesenchymal Stem Cell Therapy in Aging Frailty: A Systematic Review"],"prefix":"10.3390","volume":"27","author":[{"given":"Eleni","family":"Poutouri","sequence":"first","affiliation":[{"name":"MSc Program \u201cStem Cells and Regenerative Medicine\u201d, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sotiropoulou","sequence":"additional","affiliation":[{"name":"MSc Program \u201cStem Cells and Regenerative Medicine\u201d, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Potoupnis","sequence":"additional","affiliation":[{"name":"Academic Orthopedic Department, \u201cPapageorgiou\u201d General Hospital, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4350-9061","authenticated-orcid":false,"given":"Georgios","family":"Koliakos","sequence":"additional","affiliation":[{"name":"MSc Program \u201cStem Cells and Regenerative Medicine\u201d, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-2297","authenticated-orcid":false,"given":"Evanthia","family":"Kassi","sequence":"additional","affiliation":[{"name":"Centre of Expertise in Rare Endocrine Diseases, C.E.R.E.D\u2014Disorders of Calcium and Phosphate Metabolism, Endocrinology Unit, 1st Department of Propaedeutic Internal Medicine, LAIKO General Hospital of Athens, National and Kapodistrian University of Athens, 10679 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Symeon","family":"Tournis","sequence":"additional","affiliation":[{"name":"Laboratory for Research of the Musculoskeletal System \u201cTh. Garofalidis\u201d, Medical School, National and Kapodistrian University of Athens, KAT Hospital, 14561 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8949-4312","authenticated-orcid":false,"given":"Panagiotis","family":"Anagnostis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, 3rd Department of Internal Medicine, \u201cPapageorgiou\u201d General Hospital of Thessaloniki, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","article-title":"Frailty in older adults: Evidence for a phenotype","volume":"56","author":"Fried","year":"2001","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"M255","DOI":"10.1093\/gerona\/59.3.M255","article-title":"Untangling the concepts of disability, frailty, and comorbidity: Implications for improved targeting and care","volume":"59","author":"Fried","year":"2004","journal-title":"J. Gerontol. Ser. A"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(19)31786-6","article-title":"Frailty: Implications for clinical practice and public health","volume":"394","author":"Hoogendijk","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wallengren, O., Bosaeus, I., Fr\u00e4ndin, K., Lissner, L., Falk Erhag, H., Wetterberg, H., Sterner, T.R., Ryd\u00e9n, L., Rothenberg, E., and Skoog, I. (2021). Comparison of the 2010 and 2019 diagnostic criteria for sarcopenia by the European Working Group on Sarcopenia in Older People (EWGSOP) in two cohorts of Swedish older adults. BMC Geriatr., 21.","DOI":"10.1186\/s12877-021-02533-y"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jcsm.12157","article-title":"Prevalence and incidence of sarcopenia in the very old: Findings from the Newcastle 85+ Study","volume":"8","author":"Dodds","year":"2017","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12603-019-1179-9","article-title":"Prevalence and risk factors for frailty among community-dwelling older people in China: A systematic review and meta-analysis","volume":"23","author":"He","year":"2019","journal-title":"J. Nutr. Health Aging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/jgs.14317","article-title":"Prevalence of frailty and factors associated with frailty in individuals aged 90 and older: The 90+ Study","volume":"64","author":"Lee","year":"2016","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e198398","DOI":"10.1001\/jamanetworkopen.2019.8398","article-title":"Global incidence of frailty and prefrailty among community-dwelling older adults: A systematic review and meta-analysis","volume":"2","author":"Chin","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/s41569-018-0064-2","article-title":"Inflammageing: Chronic inflammation in ageing, cardiovascular disease, and frailty","volume":"15","author":"Ferrucci","year":"2018","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","article-title":"Inflammation and aging: Signaling pathways and intervention therapies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/sctm.17-0051","article-title":"Mesenchymal stem cells: Time to change the name!","volume":"6","author":"Caplan","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3727\/096368915X689622","article-title":"Clinical trials with mesenchymal stem cells: An update","volume":"25","author":"Squillaro","year":"2016","journal-title":"Cell Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Schulman, I.H., Balkan, W., and Hare, J.M. (2018). Mesenchymal stem cell therapy for aging frailty. Front. Nutr., 5.","DOI":"10.3389\/fnut.2018.00108"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: Cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"npj Regen. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.stem.2026.01.017","article-title":"Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty","volume":"33","author":"Ruiz","year":"2026","journal-title":"Cell Stem Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/gerona\/glx137","article-title":"Allogeneic mesenchymal stem cells ameliorate aging frailty: A phase II randomized, double-blind, placebo-controlled clinical trial","volume":"72","author":"Tompkins","year":"2017","journal-title":"J. Gerontol. Ser. A"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13287-024-03707-2","article-title":"Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: A phase I\/II randomized, double-blind, placebo-controlled study","volume":"15","author":"Zhu","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s12015-025-10969-7","article-title":"Exercise-activated mesenchymal stem cells: A translational strategy for age-related sarcopenia management","volume":"21","author":"Jian","year":"2025","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Yi, Y.T., Zhao, H.F., Wang, W.Z., and Li, X. (2025). Osteosarcopenia: Epidemiology, molecular mechanisms, and management. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1577758"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13287-025-04841-1","article-title":"Umbilical cord mesenchymal stromal cells in sarcopenia: Benefits and strategies for enhancing efficacy","volume":"17","author":"Yu","year":"2026","journal-title":"Stem Cell Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kwok, B.C., Pua, Y.H., Mamun, K., and Wong, W.P. (2013). The minimal clinically important difference of six-minute walk in Asian older adults. BMC Geriatr., 13.","DOI":"10.1186\/1471-2318-13-23"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14283\/jfa.2019.33","article-title":"Clinically meaningful change for physical performance: Perspectives of the ICFSR Task Force","volume":"9","author":"Guralnik","year":"2020","journal-title":"J. Frailty Aging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","article-title":"Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases","volume":"14","author":"Shi","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ebiom.2015.03.020","article-title":"Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells","volume":"2","author":"Premer","year":"2015","journal-title":"EBioMedicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"20417314211031378","DOI":"10.1177\/20417314211031378","article-title":"Injectable ROS-scavenging hydrogel with MSCs promoted the regeneration of damaged skeletal muscle","volume":"12","author":"Shan","year":"2021","journal-title":"J. Tissue Eng."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0002-8703(03)00119-4","article-title":"The 6-minute walk test: How important is the learning effect?","volume":"146","author":"Wu","year":"2003","journal-title":"Am. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jclinepi.2013.08.015","article-title":"Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects","volume":"67","author":"McCambridge","year":"2014","journal-title":"J. Clin. Epidemiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ccc.2019.12.003","article-title":"The Angiopoietin-Tie2 pathway in critical illness","volume":"36","author":"Sack","year":"2020","journal-title":"Crit. Care Clin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e59520","DOI":"10.7554\/eLife.59520","article-title":"Identification of specific Tie2 cleavage sites and therapeutic modulation in experimental sepsis","volume":"9","author":"Idowu","year":"2020","journal-title":"eLife"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13287-015-0240-9","article-title":"The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy","volume":"6","author":"Zhang","year":"2015","journal-title":"Stem Cell Res. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s12603-018-1139-9","article-title":"International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, diagnosis and management","volume":"22","author":"Dent","year":"2018","journal-title":"J. Nutr. Health Aging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.maturitas.2021.01.002","article-title":"The effect of vitamin D plus protein supplementation on sarcopenia: A systematic review and meta-analysis of randomized controlled trials","volume":"145","author":"Gkekas","year":"2021","journal-title":"Maturitas"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s41999-024-01123-6","article-title":"Cost of illness analysis of frailty for older adults: A systematic review and meta-analysis","volume":"16","author":"Pradana","year":"2025","journal-title":"Eur. Geriatr. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12603-019-1273-z","article-title":"Physical frailty: ICFSR international clinical practice guidelines for identification and management","volume":"23","author":"Dent","year":"2019","journal-title":"J. Nutr. Health Aging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"afad023","DOI":"10.1093\/ageing\/afad023","article-title":"Cost-effectiveness of physical activity programs and services for older adults: A scoping review","volume":"52","author":"Pinheiro","year":"2023","journal-title":"Age Ageing"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e081477","DOI":"10.1136\/bmj-2024-081477","article-title":"SPIRIT 2025 statement: Updated guideline for protocols of randomised trials","volume":"389","author":"Chan","year":"2025","journal-title":"BMJ"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: Updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7596\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:05:16Z","timestamp":1787648716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":43,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177596"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177596","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}